Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

296 - An investigation into the effects of prior irradiation to the tumour mass on murine TIL expansion


14 Dec 2018


Poster Display session


Alexander Azizi


Annals of Oncology (2018) 29 (suppl_10): x11-x16. 10.1093/annonc/mdy485


A. Azizi1, E. Cheadle1, A. Popple1, T. Illidge2

Author affiliations

  • 1 Targeted Therapy Group, Manchester Cancer Research Centre, M20 4GJ - Manchester/GB
  • 2 Targeted Therapy Group, Manchester Cancer Research Centre, M20 4BX - Manchester/GB


Abstract 296


Tumour infiltrating lymphocyte (TIL) therapy extracts CD8+ and CD4+ T cells from a tumour mass, expands and re-infuses them back into the patient. TIL therapy can lead to substantial complete, durable responses, particularly in refractory melanoma. TIL therapy is more effective if more T cells are infused, if they are less differentiated and if they target tumour antigen. Radiotherapy (RT) prior to TIL extraction may have immunostimulatory effects and so increase T cell infiltration into tumours, alter the T cell phenotype or increase number of tumour specific T cells in the expanded TIL.


Two murine melanoma models (B16 and 4434) were grown in CD57Bl/6 mice. Treated tumours were irradiated with single dose (8 Gray) local radiotherapy, harvested 72 hours later and TIL were enriched. TIL were expanded for 9-10 days ex vivo using the allosensitised allogeneic lymphocyte expansion protocol (AEP), which uses soluble growth factors and allogeneic feeder cells to stimulate T cell growth. Live expanded TIL were counted using a haemocytometer, phenotyped using fluorescence-activated cell sorting and assayed for tumour reactivity by interferon gamma production.


CD8 + (≤ 61 fold) and CD4 + (≤ 16 fold) murine T cells expanded using the AEP in both murine tumour lines. 4434-derived and B16-derived TIL expanded to similar numbers with (n = 4) and without (n = 4) prior RT to tumour mass. When B16-derived TIL were analysed further, there were no changes in differentiation status or in the tumour reactivity (p = 0.48) of TIL from RT treated tumours. However, B16-derived TIL expanded from RT treated tumours had significantly greater expression of PD1 (as measured by percentage positive cells (p = 0.020) and geometric mean fluorescence intensity (p = 0.030)).


This is the first study to expand murine or human TIL treated with prior RT. The AEP expanded tumour reactive murine melanoma TIL to numbers (1-5 x 10cells) which might effectively treat in vivo murine models. Increased PD1 expression on TIL from RT-treated tumours might predict increased in vivo effectiveness, particularly if combined with PD1 inhibitors. The effect of different RT regimens on TIL expansion and effectiveness could be investigated with this approach.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The University of Manchester.


The University of Manchester.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.